EUVIMEDEUVIMED entdecken
Crossref

TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL

Anh Trần, Hà Lê, Anh Trần

Tạp chí Ung thư học Việt Nam · 15.04.2026

DOI: 10.70755/vnjo.2026.82.8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tạp chí Ung thư học Việt Nam, online erschienen am 15.04.2026. Verfasst von Anh Trần und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy of neoadjuvant treatment using the TCHP regimen in patients with HER2-positive breast cancer at Hanoi Oncology Hospital.



Materials and Methods: A combined retrospective and prospective cross-sectional descriptive study was conducted on patients with HER2-positive breast cancer treated with the TCHP regimen as neoadjuvant at Hanoi Oncology Hospital from January 2023 to September 2025.

Results

Among 36 enrolled patients, the average age was 48.6 years (range 30–70). There were 20 patients (55.6%) with stage II and 16 patients (44.4%) with stage III disease; 14 patients (38.9%) underwent clip placement before treatment. After 3 cycles, 7 patients (19.4%) achieved clinical complete response; after 6 cycles, this rate doubled to 14 patients (38.9%). The pathological complete response (pCR) rate was achieved in 24 patients (75%). Clinical complete response was a predictive factor for achieving pCR (p < 0.05), while no significant association was found between pCR and age, stage, histological grade, hormone receptor status, or Ki-67. No patients experienced disease progression during treatment. Most adverse events (AEs) were at grade 1–2. The most common grade 3–4 AE was neutropenia (3 patients, 8.3%). No grade 3–4 thrombocytopenia, hepatic, renal, or cardiac toxicities were observed. Two patients (5.6%) experienced grade 1 left ventricular ejection fraction reduction without requiring treatment delay.

Conclusion

The TCHP regimen demonstrates high efficacy with good tolerability and manageable, predictable AEs in patients with HER2+ breast cancer.

Zitieren

APA

Trần, A., Lê, H., & Trần, A. (2026). TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL. Tạp chí Ung thư học Việt Nam. https://doi.org/10.70755/vnjo.2026.82.8

Vancouver

Trần A, Lê H, Trần A. TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL. Tạp chí Ung thư học Việt Nam. 2026. doi:10.70755/vnjo.2026.82.8

BibTeX
@article{Trn2026,
  author = {Trần, Anh and Lê, Hà and Trần, Anh},
  title = {TREATMENT OUTCOME OF NEOADJUVANT THERAPY WITH TCHP REGIMEN IN PATIENTS WITH HER2+ BREAST CANCER AT HANOI ONCOLOGY HOSPITAL},
  journal = {Tạp chí Ung thư học Việt Nam},
  year = {2026},
  doi = {10.70755/vnjo.2026.82.8}
}
Kostenlos starten →